Esperion Therapeutics (ESPR) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 3, 2022 7:00 AM EDTUnprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation
U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew approximately 109% Y/Y to $13.4 Million in the First Quarter 2022
Retail Prescription Equivalents Grew 56.7% Year over Year
ANN ARBOR, Mich., May 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
"During the first quarter of 2022, our team remained focused on our two primary... More
